HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Giuseppe Giaccone Selected Research

High-Q-Bond (Ideal 1)

6/2004The role of gefitinib in lung cancer treatment.
6/2003Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Giuseppe Giaccone Research Topics

Disease

171Neoplasms (Cancer)
11/2022 - 01/2002
103Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 02/2002
51Lung Neoplasms (Lung Cancer)
01/2022 - 10/2002
21Thymoma (Thymic Carcinoma)
01/2022 - 03/2005
13Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2022 - 10/2002
13Disease Progression
12/2018 - 03/2004
10Diarrhea
01/2019 - 03/2004
9Adenocarcinoma
01/2020 - 03/2004
8Neoplasm Metastasis (Metastasis)
01/2020 - 02/2002
7Carcinoma (Carcinomatosis)
12/2016 - 07/2002
6Exanthema (Rash)
01/2019 - 11/2005
6Pancreatic Neoplasms (Pancreatic Cancer)
12/2018 - 08/2005
5Thrombocytopenia (Thrombopenia)
11/2014 - 03/2002
4Adenocarcinoma of Lung
11/2016 - 01/2012
4Melanoma (Melanoma, Malignant)
01/2016 - 09/2010
3Nausea
10/2017 - 03/2002
3Hematologic Neoplasms (Hematological Malignancy)
01/2016 - 11/2005
3Neutropenia
11/2014 - 06/2007
3Carcinogenesis
10/2013 - 08/2005
3Prostatic Neoplasms (Prostate Cancer)
09/2012 - 07/2010
3Lymphoma (Lymphomas)
01/2012 - 11/2005
3Thymus Neoplasms (Thymus Neoplasm)
02/2011 - 10/2010
3Malignant Mesothelioma
11/2006 - 10/2005
3Fanconi Anemia (Fanconi's Anemia)
01/2005 - 06/2003
3Hypersensitivity (Allergy)
01/2005 - 06/2003
3Infections
12/2004 - 02/2002
2Esophageal Neoplasms (Esophageal Cancer)
09/2021 - 04/2006

Drug/Important Bio-Agent (IBA)

39ErbB Receptors (EGF Receptor)IBA
01/2020 - 06/2003
27Tyrosine Kinase InhibitorsIBA
01/2018 - 06/2003
22Cisplatin (Platino)FDA LinkGeneric
01/2019 - 03/2002
20Gefitinib (Iressa)FDA Link
01/2019 - 06/2003
16Proteins (Proteins, Gene)FDA Link
01/2022 - 12/2004
16Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2020 - 08/2005
15Biomarkers (Surrogate Marker)IBA
01/2022 - 02/2008
15DNA (Deoxyribonucleic Acid)IBA
09/2021 - 08/2005
14Pharmaceutical PreparationsIBA
01/2022 - 07/2005
11Paclitaxel (Taxol)FDA LinkGeneric
12/2021 - 02/2002
10PlatinumIBA
01/2021 - 06/2002
10Biological ProductsIBA
01/2020 - 11/2002
8Histone Deacetylase InhibitorsIBA
01/2018 - 11/2008
8Bortezomib (Velcade)FDA Link
09/2009 - 11/2005
7Monoclonal AntibodiesIBA
10/2020 - 06/2003
7Phosphotransferases (Kinase)IBA
01/2019 - 01/2002
7dacomitinibIBA
01/2019 - 10/2010
7Anaplastic Lymphoma KinaseIBA
05/2016 - 11/2012
7GemcitabineFDA Link
04/2012 - 03/2002
7CaspasesIBA
04/2007 - 02/2002
6pembrolizumabIBA
01/2022 - 10/2017
6Heat-Shock Proteins (Heat-Shock Protein)IBA
12/2021 - 01/2010
6LigandsIBA
11/2021 - 12/2002
5Immune Checkpoint InhibitorsIBA
11/2022 - 02/2014
5atezolizumabIBA
11/2021 - 10/2017
5Pemetrexed (MTA)FDA Link
06/2019 - 04/2008
5belinostatIBA
01/2018 - 05/2011
5Doxorubicin (Adriamycin)FDA LinkGeneric
01/2018 - 10/2002
5Sorafenib (BAY 43-9006)FDA Link
04/2012 - 09/2009
4Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022 - 11/2013
4B7-H1 AntigenIBA
01/2022 - 10/2017
4Carboplatin (JM8)FDA LinkGeneric
12/2021 - 03/2004
4NivolumabIBA
10/2021 - 12/2016
4AntigensIBA
11/2016 - 09/2011
4CrizotinibIBA
01/2016 - 01/2012
4Sunitinib (Sutent)FDA Link
02/2015 - 09/2008
4Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
11/2013 - 11/2006
4MicroRNAs (MicroRNA)IBA
10/2013 - 07/2010
4Tyrosine (L-Tyrosine)FDA Link
06/2012 - 01/2002
4Proteasome InhibitorsIBA
11/2007 - 11/2005
3MesothelinIBA
01/2022 - 05/2015
3osimertinibIBA
01/2021 - 10/2017
3Cell-Free Nucleic AcidsIBA
12/2018 - 12/2017
3STA 9090IBA
01/2018 - 12/2010
3Etoposide (VP 16)FDA LinkGeneric
01/2018 - 10/2002
3Proteasome Endopeptidase Complex (Proteasome)IBA
01/2017 - 11/2005
3VaccinesIBA
01/2016 - 07/2010
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2016 - 09/2010
3CytokinesIBA
01/2016 - 12/2004
3Bevacizumab (Avastin)FDA Link
10/2015 - 04/2007
3Docetaxel (Taxotere)FDA Link
10/2015 - 03/2004
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
08/2015 - 10/2002
3Epidermal Growth Factor (EGF)IBA
04/2014 - 07/2010
3Peptides (Polypeptides)IBA
06/2012 - 09/2009
3Imatinib Mesylate (Gleevec)FDA Link
01/2012 - 10/2009
3EpitopesIBA
09/2011 - 08/2004
3ParaffinIBA
11/2010 - 01/2007
3SurvivinIBA
09/2009 - 04/2002
3Caspase 9IBA
05/2009 - 06/2006
3Antineoplastic Agents (Antineoplastics)IBA
03/2009 - 01/2002
2Messenger RNA (mRNA)IBA
01/2022 - 12/2012
2SNX-5422IBA
12/2021 - 11/2011
2Dasatinib (BMS 354825)FDA Link
01/2021 - 01/2018
2citrate-binding transport proteinIBA
01/2020 - 01/2018
2Somatostatin Receptors (Somatostatin Receptor)IBA
01/2020 - 01/2020

Therapy/Procedure

85Therapeutics
01/2022 - 03/2002
52Drug Therapy (Chemotherapy)
01/2022 - 03/2002
13Immunotherapy
11/2022 - 07/2010
11Radiotherapy
09/2021 - 11/2002
4Neoadjuvant Therapy
09/2021 - 03/2005
3Lasers (Laser)
10/2021 - 01/2012
3Adjuvant Chemotherapy
01/2018 - 10/2003
2Precision Medicine
10/2021 - 03/2014